Please assess the completion status of the following clinical trial:

Trial Title: Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Meets criteria for All-cause Dementia according to NIA-AA guidelines~2. Meets clinical criteria for one of the following disorders: Dementia associated with Parkinson's disease, Dementia with Lewy bodies, Possible or probable Alzheimer's disease, Frontotemporal degeneration spectrum disorders, Vascular dementia~3. Has an MMSE score ≥6 and ≤24~4. Has had psychotic symptoms for at least 2 months~5. Must be on a stable does of cholinesterase inhibitor or memantine, if applicable~6. If the subject is female, she must not be pregnant or breastfeeding. She must also be of non-childbearing potential or must agree to use a clinically acceptable method of contraception for the duration of the study~Exclusion Criteria:~1. Has psychotic symptoms that are primarily attributable to a condition other than dementia~2. Has had a recent major depressive episode~3. Has experienced suicidal ideation or behavior within 3 months prior to study enrollment~4. Has evidence of a non-neurologic medical comorbidity or medication use that could substantially impair cognition~5. Has a history of ischemic stroke within the last 12 months or any evidence of hemorrhagic stroke~6. Has a known history of cerebral amyloid angiopathy (CAA), epilepsy, CNS neoplasm, or unexplained syncope~7. Has any of the following: greater than New York Heart Association (NYHA) Class 2 congestive heart failure, Grade 2 or greater angina pectoris, sustained ventricular tachycardia, ventricular fibrillation, torsade de pointes, syncope due to an arrhythmia, an implantable cardiac defibrillator~8. Had a myocardial infarction within the last 6 months~9. Has a known personal or family history or symptoms of long QT syndrome~10. Has a significant unstable medical condition that could interfere with subject's ability to complete the study or comply with study procedures~11. Requires treatment with a medication or other substance that is prohibited by the protocol~Additional inclusion/exclusion criteria apply. Subjects will be evaluated at screening to ensure that all criteria for study participation are met.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- Drug - Pimavanserin (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).